It’s just got tougher for biotech companies – especially those at an early-stage where risk is greater – to access the talent essential to develop a successful business. 9 May 2022
The refusal of large pharmaceutical manufacturers to conduct their clinical trials in Russia threatens local specialized centers with the loss of almost half of potential contracts, according to recent statements by some local analysts in the field of pharmaceutics and Russian media reports, reports The Pharma Letter’s local correspondent. 4 May 2022
None of the global drugmakers operating in the Russian market has announced plans to terminate the supplies of their drugs to the country, according to recent statements by an official spokesman of the Russian healthcare regulator Roszdravnadzor, while some of them are even considering the increase of supplies, reports The Pharma Letter’s local correspondent. 4 May 2022
India continues to establish itself as the pharmacy of the world as exports swell by 103% since 2013-14. The pharmaceutical industry is now being urged to work toward becoming the healthcare custodian of the world by adhering to good manufacturing practices, reports The Pharma Letter’s India correspondent. 3 May 2022
An Expert View from Neelam Patel, chief executive of MedCity, a not-for-profit that serves as the life sciences cluster organization for London. 2 May 2022
Fibrodysplasia ossificans progressiva (FOP) is a rare connective tissue disease characterized by heterotopic ossification, where bone growth occurs in areas where bone typically should not be present.1 30 April 2022
The Russian government will allocate additional 23 billion roubles ($305 million) for the procurements of high-priced imported drugs as part of 14 high-cost nosologies (VZN) state program, reports The Pharma Letter’s local correspondent. 25 April 2022
Rare diseases powerhouse Alexion was last year acquired for $39 billion by the Anglo-Swedish pharma major AstraZeneca, becoming part of one of big pharma’s most successful companies in recent years. 22 April 2022
India is well on its way to becoming a global hub for pharmaceuticals. Around 35 active pharmaceutical ingredients (API), which were previously imported into India, are now being manufactured across the country. Applied research for investigational new drugs has also quadrupled in India, reports The Pharma Letter’s India correspondent. 21 April 2022
The development of pediatric therapies faces numerous obstacles in the pharmaceutical industry. Among these obstacles are reluctance to expose children to potential harm from experimental therapies, fear of increased liability from pediatric studies, and lack of incentive because of the small market share represented by several pediatric medicines.1 19 April 2022
A Feature on the Japanese pharma market from Patrick Branch, a Partner in LEK's Tokyo office and a member of the firm’s Life Sciences practice. 8 April 2022
The Russian Ministry of Health has prepared a list of 39 anticancer drugs that are likely to be in short supply in the country due to ongoing military conflict between Ukraine and Russia and Western sanctions imposed on Russia, reports The Pharma Letter’s local correspondent. 7 April 2022
In recent years there has been an explosion of digital tools in the life sciences, but as with everything in pharma and biotech, their value hinges on the strength of the underlying data, making it essential to capture research in a robust way. One company, Labstep, aims to help scientists achieve this. 5 April 2022
India's TB Prevalence Survey 2019-2021, the first of its kind in the country in 55 years, has found that tuberculosis (TB) is more prevalent in India than previously thought. 31 March 2022
The Ministry of Health has begun collecting data on drugs that are not produced in Russia as well as a number of “friendly” countries as part of its efforts to prevention their shortage in the domestic market, according to recent statements by an official spokesman of the Ministry and local media, reports The Pharma Letter’s local correspondent. 30 March 2022
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
The upcoming European Society for Medical Oncology (ESMO) Congress 2024 should provide a reminder—if it were needed—of the pace of innovation in the development of new medicines for cancer. 10 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Amid an explosion in investment and development milestones seen over the past decade, the age of radiopharmaceuticals as both diagnostics and as therapeutics is very much arriving. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
Accord Healthcare might not be as well-known as certain preeminent pharma corporations in the UK and Europe, but you would struggle to find any company making a greater contribution to the production and supply of medicines across the continent. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
CytoReason’s $80 million venture round may not have been the biggest in July, but it is one of a growing number of investor bets on AI powered drug discovery this year. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024